Panelist discusses how the second interim overall survival data from MARIPOSA-2, presented at the European Society for Medical Oncology Congress 2024, affect treatment strategies for patients with non–small cell lung cancer that has developed resistance to osimertinib.
Video content above is prompted by the following:
The second interim overall survival data from MARIPOSA-2 were presented at the European Society for Medical Oncology Congress 2024.
Please briefly discuss the updated data and the implications for second-line therapy for those currently receiving osimertinib, particularly when osimertinib is continued with platinum-based chemotherapy after resistance to osimertinib is noted.
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More